Zenas BioPharma (ZBIO) Accumulated Expenses (2023 - 2026)

Zenas BioPharma's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 66.07% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 66.07% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, up 57.44% from the prior year.
• Accumulated Expenses declined to $5.6 million in Q1 2026 per ZBIO's latest filing, from $13.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $44.5 million in Q2 2025 and bottomed at $3.4 million in Q1 2025.
• The 4-year median for Accumulated Expenses is $10.9 million (2025), against an average of $16.2 million.
• Across the five-year window, Accumulated Expenses tumbled 69.31% in 2025 and jumped 66.07% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $17.3 million in 2023, then sank by 51.99% to $8.3 million in 2024, then surged by 57.44% to $13.1 million in 2025, then tumbled by 57.05% to $5.6 million in 2026.
• Per Business Quant, the three latest ZBIO Accumulated Expenses figures stand at $5.6 million (Q1 2026), $13.1 million (Q4 2025), and $8.8 million (Q3 2025).